NeoGenomics Lifts Outlook as NGS Revenue Jumps 26% and Margins Improve
Market Chameleon (Wed, 29-Jul 7:51 AM ET)
NeoGenomics stock jumps 15% after beat and raise
Seeking Alpha News (Wed, 29-Jul 11:09 AM ET)
TipRanks (Wed, 29-Jul 7:55 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Wed, 29-Jul 7:32 AM ET)
Analysts Offer Insights on Healthcare Companies: Novartis (NVS) and NeoGenomics (NEO)
TipRanks (Wed, 29-Jul 7:00 AM ET)
TipRanks (Wed, 29-Jul 4:55 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)
TipRanks (Wed, 29-Jul 1:50 AM ET)
NeoGenomics Non-GAAP EPS of $0.05 beats by $0.02, revenue of $202M beats by $5.01M
Seeking Alpha News (Tue, 28-Jul 4:11 PM ET)
NeoGenomics Reports Second Quarter 2026 Results
Business Wire (Tue, 28-Jul 4:05 PM ET)
Here are the major earnings after the close Tuesday
Seeking Alpha News (Tue, 28-Jul 10:00 AM ET)
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Neogenomics trades on the NASDAQ stock market under the symbol NEO.
As of July 31, 2026, NEO stock price declined to $15.73 with 615,870 million shares trading.
NEO has a beta of 1.13, meaning it tends to be more sensitive to market movements. NEO has a correlation of 0.04 to the broad based SPY ETF.
NEO has a market cap of $2.02 billion. This is considered a Mid Cap stock.
Last quarter Neogenomics reported $202 million in Revenue and $.05 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.04.
In the last 3 years, NEO traded as high as $21.22 and as low as $4.72.
The top ETF exchange traded funds that NEO belongs to (by Net Assets): IJR, FBT, VTI, IWM, VB.
NEO has outperformed the market in the last year with a price return of +208.4% while the SPY ETF gained +18.4%. NEO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +69.9% and +6.0%, respectively, while the SPY returned +3.7% and -1.0%, respectively.
NEO support price is $15.42 and resistance is $16.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEO shares will trade within this expected range on the day.